Honorary Research Associate, Centre for the AIDS Programme of Research in South Africa (CAPRISA). Associate Member of the Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, UCT. Senior lecturer, NRF Research Career Advancement Fellow and Carnegie Corporation Emerging Academic Leaders Awardee, Division of Medical Virology, Department of Pathology. Institute of Infectious Disease and Molecular MedicineĮmail: site: | Contact details | Group members | Collaborations
See publications and profile on Research Gate. Use of ARV Drug Levels in DBS to Assess and Manage ART Adherence in South Africa (ADD-ART) Urine tenofovir point-of-care test to identify patients in need of ART adherence support (UTRA study) NIH/R01AI152119 (PI: Van Zyl, Orrell, Gandhi) –.SUpporting Sustained HIV Treatment Adherence after Initiation EDCTP (TMA2019 SFP-2812 (PI: Orrell) - Improving RETention and viral load outcomes for people taking Antiretroviral therapy through early IdentificatioN of missed doses.Use of long-acting injectable ART among Adolescent and Young Adults in South Africa (AFINaty) Viiv/Johnson and Johnson (PI: Orrell).Key areas of expertise: Adherence to ART, retention in HIV care and ART drug pharmacology and resistance. Here they use scalable interventions including text messaging, differentiated care, lay counselor-based motivational interviewing, and peer education to improve adherence and retention in typical South African ART (antiretroviral therapy) clinics and it is at the confluence of novel approaches to therapeutics and medication adherence that the core of her research work at DCAT is focused. The research at D-CAT focuses on novel methods to monitor and improve adherence to HIV and TB medication in a resource-poor setting, including through the use of electronic pillboxes and therapeutic drug monitoring. Over the past 20 years of work in the antiretroviral field, she has developed a deep interest in factors promoting the success of antiretroviral therapy when delivered in a resource-poor setting to large numbers of people, including adherence, retention in care and task-shifting to other staff cadres.
She has in-depth experience conducting research in both state-of-the-art research facilities at UCT, including the Groote Schuur CRS, which is a HPTN and HVTN-affiliated site, and the DTHF Clinical Trials Unit, as well as in primary healthcare clinic environments, where she leads a DAIDS -approved non-networked research site in Gugulethu, the DTHF Centre for Adherence and Therapeutics (D-CAT) within the Gugulethu community.Ĭatherine is an experienced HIV clinician who played an integral role in developing a number of HIV care and treatment services in the Cape Town area. She has been principal investigator on 20 clinical trials and sub-investigator on more than 30 trials of antiretroviral drugs, including a range of efficacy, toxicity, interaction and dosing studies.
Flow free bridges 7x7 level 12 full#
Clinical Lead for the DTHF Centre for Adherence and Therapeutics (D-CAT) Pharmacokinetic Study Leader at the Groote Schuur Hospital Clinical Research Site, Department of Medicine, Faculty of Health Sciences, University of Cape Town Full Member, Institute of Infectious Disease and Molecular Medicine (IDM).Ĭatherine Orrell is a clinical pharmacologist and clinical trials specialist who has worked as principal and co-investigator in clinical research at the DTHF since 1998.
0 kommentar(er)
